Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: A real-world comparison of efficacy and ocular comfort

Advances in Therapy

Volumn 20, Issue 2, 2003, Pages 79-91

  Ganz, Michael ^a   Koll, Elizabeth ^a   Gausche, Jean ^a   Detjen, Paul ^b   Orfan, Nicholas ^c  

^a Ganz Allergy and Asthma Center   (United States)

^b Kenilworth Medical Associates   (United States)

^c NONE

Author keywords

Allergic conjunctivitis; Environmental study; Ketotifen fumarate; Ocular itching; Olopatadine; Tolerability

Indexed keywords

KETOTIFEN FUMARATE; OLOPATADINE;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE BURNING; EYE IRRITATION; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPEREMIA; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; PARALLEL DESIGN; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0038208099     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850255     Document Type: Article

References (22)

1. Abelson MB, George MA, Garofolo C. Differential diagnosis of ocular allergic disorders. Ann Allergy. 1993;70:95-107.
2. Buckley RJ. Allergic eye disease: a clinical challenge. Clin Exp Allergy. 1998;28(suppl 6):39-43.
3. Friedlander MH. A review of the causes and treatment of bacterial and allergic conjunctivitis. Clin Ther. 1995;17:800-809.
4. McGill JI, Holgate ST, Church MK, Bacon A. Allergic eye disease mechanisms. Br J Ophthalmol. 1998;82:1203-1214.
5. Bacon AS, Ahluwalia P, Irani A-M, et al. Tear and conjunctival changes during the allergen-induced early- and late-phase response. J Allergy Clin Immunol. 2000;106:948-954.
6. 1 receptors in the human ocular surface. Invest Ophthalmol Vis Sci. 1981;20(suppl):32.
7. 2 receptors in the human ocular surface. Arch Ophthalmol. 1981;99:302-303.
8. Bielory L. Allergic and immunologic disorders of the eye, part II: ocular allergy. J Allergy Clin Immunol. 2000;106:1019-1032.
9. Friedlander MH. Management of ocular allergy. Ann Allergy Asthma Immunol. 1995;75:212-222.
10. Yanni JM, Sharif NA, Gamache DA, Miller ST, Weimer LK, Spellman JM. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta Ophthalmol Scand. 1999;77:33-37.
11. Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen: a review of pharmacodynamic and pharmacokinetic properties and therapeutic use in asthma and allergic disorders. Drugs. 1990;40:412-448.
12. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival challenge model. Ann Allergy Asthma Immunol. 1998;81:211-218.
13. Yanni JM, Stepjens DJ, Miller ST, et al. The in-vitro and in-vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistamine agent. J Ocul Pharmacol Ther. 1996;12:389-400.
14. Abelson MB, Welch DL. An evaluation of the onset and duration of action of Patanol® (olopatadine solution .1%) compared to Claritin® (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand. 2000;78:60-63.
15. 1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther. 1996;12:401-407.
16. Physicians' Desk Reference for Ophthalmic Medicines. 30th ed. Montvale: Medical Economics; 2001:313.
17. Physicians' Desk Reference for Ophthalmic Medicines. 30th ed. Montvale: Medical Economics; 2001:216-217.
18. Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride .1% ophthalmic solution and ketotifen fumarate .025% ophthalmic solution in the conjunctival challenge model. Clin Ther. 2000;22:826-833.
19. Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with .1% olopatadine hydrochloride versus .05% ketotifen fumarate. Acta Ophthalmol Scand. 2000;78:52-55.
20. Artal MN, Luna JD, Discepola MA. Forced choice comfort study of olopatadine hydrochloride .1% versus ketotifen fumarate .05%. Acta Ophthalmol Scand. 2000;78:64-65.
21. Abelson MB. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol. 1990;108:84-88.
22. Abelson MB. Comparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitis. Acta Ophthalmol Scand. 1999;228(suppl):38-42.